ReviewCell death discovery2026
CX3CR1-mediated immune networks in sepsis: implications for precision therapy.
Review in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is a life-threatening syndrome characterized by profound immune dysregulation in response to infection, and it remains a major cause of mortality worldwide. The CX3C chemokine receptor 1 (CX3CR1) has emerged as a pivotal regulator of sepsis-induced immune dysregulation, orchestrating the proliferation, differentiation, activation, migration, and survival of various immune cell populations, including monocytes/macrophages, natural killer cells (NK), and T cells. Emerging evidence highlights that the diverse expression patterns of CX3CR1 within distinct immune cell subsets determine its dual pro-inflammatory and anti-inflammatory effects, and CX3CR1 expression level is closely correlated with patient survival in sepsis. In addition, targeted modulation of CX3CR1 in specific immune cell types has shown promising efficacy in preclinical sepsis models. This review provides a comprehensive overview of the molecular immunoregulatory networks governed by CX3CR1, its heterogenous functions across different immune subsets, and recent advances in CX3CR1-targeted therapies, highlighting cell type-specific interventions as promising strategies for precision sepsis treatment.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.